“…Critically, ERP methods can be developed and used across species, providing the ability to translate findings readily from preclinical studies to clinical trials. Within neurodevelopmental disorders, great progress has been made in Fragile X syndrome: parallel studies on ERP in people with Fragile X syndrome and preclinical animal models suggested that they could be employed as biomarkers to evaluate disease severity or predict treatment response ( Ethridge et al, 2016 ; Ethridge et al, 2017 ; Ethridge et al, 2019 ; Lovelace, 2020 ; Sinclair et al, 2017b ; Van der Molen et al, 2012 ; Wen et al, 2019 ). Previous work in people with RTT has found changes in both visual ( LeBlanc et al, 2015 ) and auditory ERP ( Stauder et al, 2006 ), and similar changes in both visual and auditory ERPs have been observed in mouse models of RTT ( Durand et al, 2012 ; Goffin et al, 2012 ; Goffin et al, 2014 ).…”